Recent studies suggest that proinsulin-connecting peptide (C-peptide) may exhibit characteristics of a hormone and show physiological functions in various tissues. This study was aimed to determine whether C-peptide could be involved in the regulation of lipolysis, adiponectin release, and function of mesenchymal stem cells (MSCs) in adipose tissue. Human subcutaneous adipose tissue was cultured in the presence of C-peptide. The level of lipolysis was determined by glycerol measurement in the conditioned media. Effect of C-peptide on adiponectin secretion was evaluated in differentiated adipocytes. The adipogenic and osteogenic abilities of adipose MSCs were evaluated using oil red and alizarin red staining, respectively. The tetrazolium bromide test was conducted for evaluating the effect of C-peptide on MSCs proliferation. C-peptide induced a significant decrease in basal lipolysis at concentrations of 8 and 16 nM (p < 0.05). It had no significant effects on isoproterenol-stimulated lipolysis, adiponectin secretion, and adipogenic or osteogenic differentiation of MSCs. At a concentration of 4 nM, this peptide significantly increased the proliferative capability of MSCs (p < 0.05). These results suggest that C-peptide has some physiological effects in human subcutaneous adipose tissue and contributes to the regulation of basal lipolysis and pool of MSCs.
Introduction
Proinsulin-connecting peptide (C-peptide) is a cleavage product of insulin release in the pancreatic beta cells. For a long time, it has been considered as a biologically inert byproduct of insulin synthesis, and served just as an indicator of endogenous insulin secretion in diabetic patients (6) . However, recent data from several lines of studies suggest that C-peptide may exhibit characteristics of a peptide hormone and show physiological functions in various tissues (21, 53) . It increases muscle glucose transport (46) and tissue blood flow (25, 29) , and has cytoprotective and antiapoptotic effects (8) . It is now accepted that this peptide improves the function of most organs affected by diabetes complications (e.g., kidney, heart, and nerve) and administration of C-peptide together with the classic insulin therapy may prevent, retard, or ameliorate diabetic complications in patients with type-1 diabetes (21, 52, 53) . For example, clinical studies have shown that combination of C-peptide and insulin can ameliorate nephropathy and neuropathy in diabetic patients (28, 52) .
Diabetic patients show a spectrum of abnormalities in lipid metabolism including increased serum lipids, uncontrolled lipolysis, and dysregulation of adipogenesis and lipogenesis in adipose tissue. These abnormalities are associated with the development of atherosclerosis and cardiovascular diseases (4, 24, 34) . In addition, there are some reports that diabetes may impair some abilities of mesenchymal stem cells (MSCs). For example, decreased mobilization ability of bone marrow MSCs and decreased wound-healing capability of adipose tissue MSCs have been demonstrated in the patients with type 1 and type 2 diabetes (7, 12) .
Although insulin-like actions of C-peptide have been reported in some tissues, such as muscle, the effects of C-peptide on adipose tissue, the main target organ of insulin involved in lipid metabolism, are not yet well known. In our previous studies on normal and diabetic rats, we observed that this peptide may conditionally act as an antilipolytic hormone (19, 20) . The aim of this study was to examine whether C-peptide could be involved in the regulation of lipolysis, adiponectin secretion, and proliferation and differentiation abilities of MSCs in human subcutaneous adipose tissue.
Materials and Methods

Chemical compounds
High glucose Dulbecco's Modified Eagles Medium (DMEM), fetal bovine serum (FBS), and trypsin were purchased from Gibco (Grand Island, NY, USA). Dimethyl sulfoxide (DMSO), fatty acid-free bovine serum albumin fraction V, glycerol assay reagent, isoproterenol (ISO), human adiponectin enzyme-linked immunosorbent assay (ELISA) kit, penicillin-streptomycin solution, type-II collagenase, 3-isobutyl-1-methylxanthine, 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT), and 4-(2-hydroxyethyl) piperazine-1-ethanesulfonic acid sodium salt (HEPES) were obtained from Sigma-Aldrich (St. Louis, MO, USA). Human C-peptide was purchased from Bachem (Bubendorf, Switzerland). Human insulin and indomethacin were kindly provided by Exir Company, Iran. Fluorescein isothiocyanate-conjugated antibodies against CD34, CD44, CD45, and CD105 were bought from AbD Serotec (Raleigh, NC, USA).
Subjects
The subcutaneous adipose tissue samples were obtained from patients (35-55 years, body mass index less than 30 kg/m 2 ) undergoing conventional intra-abdominal surgery (cholecystectomy and hernia repair). Pregnant women and patients with serious diseases such as cancer, infections, and autoimmune diseases were excluded. The study protocols were reviewed and approved by the Ethics Committee of the Mashhad University of Medical Sciences. Informed written consent was obtained from each volunteer for obtaining a subcutaneous fat sample.
Lipolysis study
The effect of C-peptide on lipolysis was evaluated in ex vivo organ culture condition. The tissue samples were minced into small slices with a sterile procedure, washed with phosphatebuffered saline (PBS), and dried on the sterile gauze. Then, the tissue slices were precisely weighed and distributed into 24-well plates (100 mg/well). For basal lipolysis assessment, the tissue slices were cultured for 24 h in serum-free DMEM (1 ml/well) in the presence or absence of 4-16 nM C-peptide at 37°C in an atmosphere of 5% CO 2 . For stimulated lipolysis assessment, the tissue slices were distributed into a 24-well plate (100 mg/well) containing 1 ml/well Krebs-Ringer bicarbonate buffer (118 mM NaCl, 4.8 mM KCl, 1.3 mM CaCl 2 , 1.2 mM MgSO 4 , 1.2 mM KH 2 PO 4 , and 10 mM NaHCO 3 ) supplemented with 5.5 mM glucose, 25 mM HEPES, and 2% (w/v) bovine serum albumin (16) . Then, the tissues were treated for 90 min with 1 μM ISO (a non-selective beta-adrenergic receptor agonist) and 4-16 nM C-peptide under constant shaking at 37°C. The level of lipolysis was determined by measurement of glycerol in the conditioned media using glycerol assay reagent based on an enzymatic method.
Isolation and characterization of MSCs
Adipose tissue samples were minced into small slices, washed with PBS, and incubated in PBS containing collagenase (2 mg/ml) under constant shaking at 37°C (17) . After 90 min, the digested tissues were centrifuged for 5 min at 2,000 rpm and the floated lipid layer was discarded. The precipitated stromal cells were washed with PBS and then cultured in 25-cm 2 flasks containing DMEM supplemented with 10% FBS, 100 μg/ml streptomycin, and 100 IU/ml penicillin. After 24 h, non-adherent cells were discarded and anchored cells were expanded over three passages. To confirm MSC phenotype of isolated cells, they were incubated with antibodies against cell surface antigens CD34, CD44, CD45, and CD105 for 30 min at 4°C. After washing with PBS, the cells were suspended in PBS supplemented with 2% FBS and then flow cytometric analysis was performed using an FACSCalibur (BD Biosciences, San Jose, USA) flow cytometer.
Cell proliferation assay
The effect of C-peptide on the proliferation of MSCs was evaluated using MTT assay. The cells from passage 3 were seeded in 96-well culture plates (5 × 10 3 cells/well) in DMEM supplemented with 100 μg/ml streptomycin, 100 IU/ml penicillin, and 10% FBS. After 24 h, the culture media was changed by a fresh one containing 1-64 nM C-peptide. The cells were incubated for either 24 h or 48 h at 37°C in an atmosphere of 5% CO 2 . Then, MTT was added to the media at a final concentration of 0.5 mg/ml. After 3 h, the media was discarded and the precipitated formazan dye was dissolved in DMSO. The absorbance of the dye was measured at 545 nm using a StatFax303 plate reader.
Adipogenic differentiation assay
The MSCs at passage 3 were seeded in 12-well plates (5 × 10 4 cells per well) and cultured for 24 h in DMEM supplemented with 10% FBS, 100 μg/ml streptomycin, and 100 IU/ml penicillin. Then, for adipogenic induction, the cells were incubated with the differentiation medium consisting of DMEM supplemented with 3% FBS, 5 μM indomethacin, and 1 μM dexamethasone, in either the presence or absence of 0.2 μM insulin or 16 nM C-peptide. The cells were maintained in adipogenic medium for 12 days; meanwhile, the medium was replaced every 3 days. Then, the cells were fixed with 10% formalin and stained with oil red O dye, which stains intracellular triglycerides in differentiated adipocytes. After washing thrice with PBS, 200 μl isopropanol was added to each well to elute the stain from cells and its optical density was measured at 545 nm (2).
Osteogenic differentiation assay
The MSCs at passage 3 were seeded in 12-well plates (5 × 10 4 cells per well) and cultured for 24 h in DMEM supplemented with antibiotics and 10% FBS. For osteogenic induction, the cells were further cultured in a differentiation medium consisting of DMEM supplemented with 10% FBS, 10 μg/ml ascorbic acid, 5 mM β-glycerol phosphate, and 0.1 μM dexamethasone in the presence or absence of 4-16 nM C-peptide. The cells were maintained in the osteogenic medium for 2 weeks and the medium was replaced every 3 days. Then, the cells were fixed with formalin and stained with alizarin red dye which stains calcium-rich mineral deposits excreted by differentiated cells. After washing the wells thrice with PBS, 400 μl 0.5N HCl-5% sodium dodecyl sulfate solution was added to each well to solubilize the stain and its optical density was measured at 405 nm (3).
Adiponectin release assay
The effect of C-peptide on adiponectin secretion was evaluated in differentiated adipocytes. Initially, MSCs were seeded in 6-well plates (1 × 10 5 cells/well) and differentiated into adipocytes as described above. Then, the differentiated adipocytes were incubated in serum-free DMEM containing 4, 8, or 16 nM of C-peptide for 24 h at 37°C in an atmosphere of 5% CO 2 . The level of adiponectin in condition media was measured with ELISA method.
Statistical analysis
Data were analyzed by one-way analysis of variance, followed by Tukey's post hoc test. The results were presented as mean ± standard error of mean (SEM). They were considered to be statistically significant when p values were less than 0.05. Table I demonstrates the effect of C-peptide on adipose tissue lipolysis. The presence of 8 and 16 nM of C-peptide in the culture medium reduced the level of lipolysis to 83% ± 6% and 83% ± 4% of the basal level, respectively (p < 0.05). Regarding stimulated lipolysis, ISO (1 μM) led to a significant elevation in lipolysis (p < 0.01) as expected.
Results
Effect of C-peptide on lipolysis
C-peptide at the tested concentrations had no significant effect on ISO-stimulated lipolysis.
Characterization of MSCs
Flow cytometric analysis showed that the MSCs isolated in this work were positive for stem cell-associated markers CD44 and CD105, and consistently negative for hematopoietic markers CD34 and CD45.
Effect of C-peptide on MSCs proliferation
As shown in Fig. 1A , incubation with 4 nM C-peptide for 24 h significantly increased proliferation of MSCs compared with untreated cells (136% ± 13% vs. 100% ± 3%, p < 0.05). Similarly, after 48 h incubation, C-peptide could significantly (12%, p < 0.05) enhance proliferation of MSCs only at a concentration of 4 nM (Fig. 1B) . Figure 2 shows the effect of C-peptide on osteogenic differentiation of MSCs. Incubation of the differentiating cells with C-peptide concentrations of 4, 8, and 16 nM had no effect on osteogenesis as evaluated with alizarin red staining of the extracellular calcium deposit. Figure 3 demonstrates the effect of insulin and C-peptide on adipogenic differentiation of MSCs. The addition of insulin to the differentiation medium promoted the accumulation of intracellular lipid droplets. On the other hand, C-peptide at the tested concentration (16 nM) failed to induce adipogenic differentiation of MSCs. It also failed to enhance the stimulatory effect of insulin on intracellular lipid droplet accumulation. 
Effects of C-peptide on MSCs differentiation
Effects of C-peptide on basal and stimulated lipolysis in human subcutaneous adipose tissue
Effect of C-peptide on adiponectin release
The effect of C-peptide on adiponectin secretion from differentiated adipocytes is shown in Fig. 4 . In the presence of 4, 8, and 16 nM of this peptide, concentrations of adiponectin in culture media were 11 ± 2 ng/ml, 9.8 ± 2 ng/ml, and 8.7 ± 2.5 ng/ml, respectively, which were not statistically different from the value measured in the medium of untreated cells (8.3 ± 2.5 ng/ml).
Discussion
This is the first study to show that C-peptide decreases lipolysis and increases proliferation of MSCs in human adipose tissue. These results rule out the earlier view that that C-peptide is biologically inert and supports the current suggestion that it not only plays an important role in the synthesis of insulin but also acts as a peptide hormone. The adipose tissue is one of the largest compartments in the body and has many physiological functions including energy storage and hormone secretion (1, 32) . During times of energy excess, it accumulates triglyceride through lipogenesis and adipogenesis processes, and during calory insufficiency, it delivers the stored triglyceride through the activation of lipolysis (10) . This tissue is one of the main target organs of insulin, where it stimulates lipogenesis and adipogenesis, and inhibits lipolysis (18, 21, 31, 35, 45) . Lipolysis is under the control of the endocrine and the nervous systems. Catecholamines stimulate lipolysis through beta-adrenergic receptors, which enhance adenylate cyclase activity, and raise intracellular production of cyclic adenosine monophosphate (cAMP). The increased cAMP results in activation of protein kinase A and subsequent activation of hormone sensitive lipase. On the other hand, insulin inhibits lipolysis by activating the phosphodiesterase-3B and consequently MSCs were maintained in osteogenic medium for 2 weeks in the presence of C-peptide and the level of differentiation was quantified by measuring the optical density of alizarin red which stains calcium deposits reduces cAMP level (35) . This data showed that C-peptide, at concentrations of 8 and 16 nM, decreases lipolysis in the basal state and therefore possesses insulin-like action on lipolysis. This effect is most probably mediated by activating phosphodiesterase-3B in adipocytes (20) . Insulin deficiency as seen in type-1 diabetes is associated with increased lipolysis that ultimately results in severing fat loss and even diabetic ketoacidosis (22, 43) . Because of the antilipolytic property of C-peptide, coreplacement of insulin and C-peptide may prevent, retard, or ameliorate such diabetes-related complications. In our previous works on the visceral adipose tissue of normal rats, the inhibitory effect of C-peptide (6 nM) on basal lipolysis remained non-significant after 90 min of incubation (19) . In this study on subcutaneous adipose tissue, we tested several concentrations of C-peptide (4, 8, and 16 nM) in an incubation period of 24 h and observed significant antilipolytic action at concentrations ≥8 nM. In addition to species-related differences or incubation period, anatomical depot-related differences in lipolytic activity of adipose tissues may explain the differing results. Several studies have reported that there are fat depot-related differences with regard to glucose uptake (48, 51) , endocrine function (38, 39) , and lipolysis (5, 44, 50, 55) . The subcutaneous adipose tissue shows higher basal lipolysis than visceral fat depots. On the other hand, catecholamines-induced lipolysis is more pronounced in visceral than subcutaneous fat (5, 44, 50, 55) . In addition, some antilipolytic agents including insulin and clonidine exert a more potent antilipolytic effect on subcutaneous than visceral adipocytes (44, 55) . Therefore, the possibility that C-peptide might affect basal lipolysis in a depot-specific manner should be tested in humans by future studies. In addition, biological effects of C-peptide may be varied depending on the metabolic status of the body. There are some reports which suggest that certain actions of C-peptide appear only in diabetes and not in normal condition (33, 41) . Consistent with this hypothesis, results of this study and our previous works (19, 20) showed that C-peptide significantly inhibited ISO-stimulated lipolysis in untreated diabetic rats, whereas it virtually had no effect on the stimulated lipolysis in insulin-treated rats and in non-diabetic subjects.
White adipose tissue secretes a large number of endocrine factors, called adipokines, such as adiponectin, leptin, resistin, and visfatin. Inappropriate secretion of adipokines is known to be involved in the development of obesity-related pathologies including atherosclerosis, diabetes, and inflammation (9) . The effects of C-peptide on endocrine function of subcutaneous adipose tissue are not yet well known. Recently, Garcia-Serrano et al. (15) demonstrated that this peptide at concentrations of 1 and 10 nM increased leptin and decreased visfatin secretion from human visceral fat. In this study, the effect of C-peptide on adiponectin secretion was investigated in human subcutaneous adipocytes. Adiponectin is a secretory protein, which promotes beta cell survival and function, decreases serum glucose by reducing hepatic glucose output, increases adipocyte number, and induces local and systemic anti-inflammatory effects (49) . Decreased adiponectin level is associated with insulin resistance, metabolic syndrome, and extension of coronary artery disease (11, 54) . Strategies to increase adiponectin have been suggested as an approach for management of adipose tissue-linked diseases, such as diabetes and insulin resistance (54) . This data showed that C-peptide at 4 nM induced a non-significant increase (approximately 32%) in adiponectin secretion. This effect was attenuated at higher concentrations of C-peptide (8 and 16 nM), suggesting that the effect might be significant at C-peptide concentrations of <4 nM. However, Garcia-Serrano et al. (15) reported that C-peptide at 1 nM did not significantly alter the adiponectin secretion in visceral fat. Considering the aforementioned fat depotrelated differences, further works are suggested to elucidate the effect of lower concentrations of C-peptide on adiponectin secretion in the subcutaneous adipose tissue.
Patients with type-1 diabetes show decreased fat mass mainly due to lack of trophic action of insulin on adipose tissue (22) . The adipose mass is determined by both the number and size of adipocytes. While the dimension of adipocytes depends on the rate of lipolysis and lipogenesis, their number is controlled by a balance between generating new adipocytes (adipogenesis) and adipocyte apoptosis (27, 47) . New adipocytes are believed to arise from resident MSCs, a process which is promoted by insulin (36) . Consistent with this, this data showed that the presence of insulin in the adipogenic culture medium is essential for differentiation of MSCs into adipocytes. However, C-peptide did not induce adipogenic differentiation of MSCs and also failed to enhance the adipogenic effect of insulin. The effect of C-peptide on adipogenesis was examined only at a concentration of 16 nM, which is one limitation of this study. Nevertheless, the inability of C-peptide in inducing differentiation was also observed regarding osteogenic differentiation of MSCs which was examined at 4, 8, and 16 nM C-peptide. On the other hand, C-peptide could increase proliferation of MSCs, suggesting that it may contribute to preserving an optimal pool of adipose MSCs required for adipogenesis and tissue repair. Nowadays, the abilities of adipose MSCs to proliferate and differentiate into diverse cell lineages, to migrate and home into damaged tissues, and to secrete several growth factors have made them attractive candidates for cell therapies and tissue engineering (42) . However, there are some challenges that need to be resolved to increase the efficiency of stem cell therapy. One of the major challenges is the limited number of stem cells that can be obtained from many tissues. One approach is to incubate stem cells in vitro with pro-proliferative hormones or growth factors to generate enough numbers of cells for subsequent cell therapy (18) . The stimulatory effect of C-peptide on the proliferation of adipose MSCs makes it a good choice for expanding stem cell number.
Proliferation and differentiation of MSCs are regulated by complex networks of transcription factors that control the expression of hundreds of proteins involved in survival and commitment of the cells to a certain phenotype. The two principal adipogenic factors, such as peroxisome proliferator-activated receptor-γ (PPARγ) and CCAAT/enhancer binding protein-α (C/EBPα), are at the center of a network of transcription factors responsible for adipogenic differentiation of MSCs (14) . On the other hand, while some transcription factors such as runt-related 2 (Runx2) and osterix are inducers of differentiation toward osteoblasts, PPARγ and C/EBPβ are considered as inhibitory factors for osteogenic differentiation of MSCs (13) . In addition to regulating differentiation, transcription factors of the C/EBP family are of fundamental importance for controlling MSCs proliferation through interaction with proteins of the cell cycle (40) . There are no sufficient data on the effects of C-peptide on the expression of transcription factors in MSCs and future studies are required in this area. Yet, in multiple cell types from multiple tissues, this peptide has been reported to stimulate several transcription factors (e.g., PPAR, Bcl-2, nuclear factor-kB, and cAMP-responsive element-binding protein) that have key roles in the control of cell processes, such as growth and apoptosis. C-peptide stimulates these factors through its own intracellular signaling or by cross talk with the insulin pathway (23, 26) . It is rational to assume that, in diabetes, deficiency in the levels or activities of insulin and C-peptide can be accompanied by dysregulation of the aforementioned transcription factors. However, the results published in the literature are not consistent; Minteer et al. (37) reported that PPAR-γ expression is not different between MSCs of non-diabetic and type 2 diabetic subjects, but Jumabay et al. (30) reported an increase in the expression of PPAR-γ and C/EBPα in MSCs of type 2 diabetic rats compared with non-diabetic rats.
In conclusion, results of this study suggest that C-peptide has physiological effects in human subcutaneous adipose tissue and contributes to the regulation of basal lipolysis and pool of MSCs. Therefore, C-peptide deficiency in type-1 diabetes may be involved in dysregulation of adipose tissue functions. These results also support the current idea that coreplacement of insulin and C-peptide in diabetic patients may prevent or even ameliorate some of the diabetes-related complications.
